{
  "meta": {
    "title": "Drugs_For_Mania_And_Depression",
    "url": "https://brainandscalpel.vercel.app/drugs-for-mania-and-depression-b372696d.html",
    "scrapedAt": "2025-11-29T18:33:48.669Z"
  },
  "questions": [
    {
      "id": 14602,
      "choices": [
        {
          "id": 58369,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Chlordiazepoxide</span></span></span></p>"
        },
        {
          "id": 58370,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Diazepam</span></span></span></p>"
        },
        {
          "id": 58371,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Lorazepam</span></span></span></p>"
        },
        {
          "id": 58372,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Flunitrazepam</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic liver disease is admitted to the hospital for alcohol withdrawal management. Given his liver condition, the healthcare team needs to choose a medication that is safe and effective for managing his withdrawal symptoms while considering the potential impact on his liver function. Which of the following agents is most appropriate for managing alcohol withdrawal in this patient with liver disease?</span></span></p>",
      "unique_key": "Q1624936",
      "question_audio": null,
      "question_video": null,
      "map_id": 36235,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Lorazepam </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Benzodiazepines (BZDs) </strong>are the <strong>drugs of choice</strong> to treat <strong>alcohol withdrawal.</strong> <strong>Chlordiazepoxide</strong> is the <strong>first choice. Diazepam</strong> is the <strong>alternative.</strong><strong> </strong>But <strong>all BZDs </strong>given in the options (<strong>Chlordiazepoxide Diazepam and flunitrazepam</strong>) are <strong>metabolized extensively</strong> by <strong>enzyme CYP3A4 In liver and active metabolites </strong>are generated. Oxazepam, Lorazepam Temazepam are <strong>not metabolized</strong> but directly <strong>conjugated </strong>therefore they are<strong> relatively safer </strong>in <strong>elderly patients </strong>and in those with<strong> liver disease.</strong> <strong>&nbsp;</strong></span><span style=\"font-size:12.0pt\">Thus, <strong>Lorazepam (option C)</strong> is a <strong>benzodiazepine</strong> that is preferred for managing <strong>alcohol withdrawal symptoms</strong> in patients with <strong>liver disease</strong>. It <strong>undergoes</strong> <strong>glucuronidation </strong>rather than oxidation. This makes<strong> lorazepam a safer option</strong> for patients with<strong> compromised liver function</strong>, as it is <strong>less likely</strong> to <strong>accumulate to toxic levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chlordiazepoxide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While chlordiazepoxide is<strong> commonly used </strong>for <strong>alcohol withdrawal,</strong> its<strong> metabolism</strong> is significantly affected by <strong>liver function,</strong> making it a<strong> less ideal choice</strong> for patients with <strong>liver disease</strong> due to the <strong>risk of accumulation and increased side effects</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Diazepam:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Diazepam is<strong> metabolized by the liver,</strong> and <strong>its active metabolites </strong>can <strong>accumulate in patients with liver disease,</strong> potentially leading to <strong>prolonged sedation and increased toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Flunitrazepam:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Flunitrazepam is also <strong>metabolized by the liver,</strong> and like <strong>diazepam,</strong> it can <strong>accumulate in patients </strong>with <strong>liver</strong> <strong>impairment,</strong> making it a <strong>less favorable option.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to understand that <strong>lorazepam</strong> is the preferred<strong> benzodiazepine</strong> for managing <strong>alcohol withdrawal symptoms in patients with liver disease </strong>due to its <strong>metabolism through glucuronidation,</strong> which is <strong>less</strong> affected by <strong>liver function</strong> compared to the<strong> oxidative metabolism</strong> of<strong> other benzodiazepines. </strong></span></span></span></p>",
      "correct_choice_id": 58371,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14596,
      "choices": [
        {
          "id": 58345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine </span></span></span></p>"
        },
        {
          "id": 58346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate </span></span></span></p>"
        },
        {
          "id": 58347,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ACTH </span></span></span></p>"
        },
        {
          "id": 58348,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vigabatrin </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 6-month-old infant presents with a history of infantile spasms and has recently been diagnosed with a visual field defect. The pediatric neurologist discusses treatment options with the parents, emphasizing the need for effective management of the spasms while also considering the potential side effects of medications. Which of the following drugs, despite being highly effective for treating infantile spasms, is not used in this patient due to the risk of exacerbating the visual defect?</span></span></p>",
      "unique_key": "Q1725512",
      "question_audio": null,
      "question_video": null,
      "map_id": 36233,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Vigabatrin </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin</strong> is a<strong> medication</strong> that is<strong> highly effective </strong>in the <strong>treatment of infantile spasms,</strong> particularly those associated with<strong> tuberous</strong> <strong>sclerosis.</strong> However, its use is associated with a<strong> risk of permanent visual field defects, </strong>making it <strong>contraindicated </strong>or used <strong>with caution</strong> in <strong>patients with pre-existing</strong> <strong>visual problems </strong>or when the<strong> risk of such adverse effects</strong> <strong>outweighs</strong> the<strong> benefits.</strong> In a child with <strong>infantile spasms</strong> and a <strong>visual defect</strong>,<strong> vigabatrin</strong> <strong>would not</strong> be the preferred <strong>choice </strong>due to this <strong>risk.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> Lamotrigine is an <strong>antiepileptic drug </strong>used for <strong>various seizure types</strong> but is <strong>not</strong> the <strong>first-line treatment</strong> for <strong>infantile spasms. </strong>It <strong>does not</strong> have a<strong> high risk </strong>of<strong> causing</strong> or <strong>exacerbating visual field defects.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Topiramate:</span></strong><span style=\"font-size:12.0pt\"> Topiramate is another <strong>antiepileptic</strong> that <strong>can be used </strong>in the management of<strong> infantile spasms</strong> but is also<strong> not</strong> primarily associated with<strong> visual field </strong>defects as a common adverse effect.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ACTH (Adrenocorticotropic hormone):</span></strong><span style=\"font-size:12.0pt\"> ACTH is a<strong> standard treatment</strong> for <strong>infantile spasms </strong>and <strong>does not</strong> directly cause <strong>visual field defects</strong>, making it a suitable option for this condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to<strong> identify vigabatrin</strong> as an <strong>effective treatment</strong> for<strong> infantile spasms</strong> that is <strong>contraindicated in patients</strong> with <strong>pre-existing visual field defects</strong> due to the<strong> risk of exacerbating or causing permanent visual damage.</strong></span></span></span></p>",
      "correct_choice_id": 58348,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14593,
      "choices": [
        {
          "id": 58333,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Psychosis</span></span></span></p>"
        },
        {
          "id": 58334,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Severe vomiting</span></span></span></p>"
        },
        {
          "id": 58335,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Arrhythmia</span></span></span></p>"
        },
        {
          "id": 58336,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Postural hypotension</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following adverse effects of Levodopa can be reduced by carbidopa except</span></span></p>",
      "unique_key": "Q7958063",
      "question_audio": null,
      "question_video": null,
      "map_id": 36231,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Psychosis</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levodopa</strong> is a <strong>precursor of dopamine,</strong> a<strong> neurotransmitter</strong> that is depleted in <strong>Parkinson&#39;s disease.</strong> It is <strong>converted into dopamine</strong> in the <strong>brain,</strong> where it <strong>stimulates dopamine receptors</strong>, including<strong> D1 and D2 receptors. Levodopa</strong> is <strong>not</strong> a<strong> dopamine receptor agonist,</strong> but rather a <strong>precursor of dopamine</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbidopa</strong> is often <strong>co-administered</strong> with<strong> levodopa</strong> to prevent<strong> its peripheral breakdown</strong> and<strong> increase its availability </strong>in the<strong> brain. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbidopa</strong> is a <strong>peripheral dopa decarboxylase inhibitor</strong> that<strong> does not cross the blood-brain barrier.</strong> It helps to <strong>reduce</strong> the <strong>peripheral adverse effects of levodopa</strong>, such as <strong>nausea and vomiting,</strong> <strong>postural hypotension,</strong> and <strong>cardiac</strong> <strong>arrhythmias, </strong>by<strong> preventing its breakdown </strong>in the <strong>gastrointestinal tract. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, <strong>carbidopa</strong> <strong>does not </strong>directly affect <strong>levodopa&#39;s activity on dopamine receptors</strong> in the brain, which is thought to be responsible for the <strong>development of psychosis as an adverse effect</strong>. Therefore,<strong> carbidopa cannot</strong> <strong>reduce</strong> the risk of developing<strong> psychosis</strong> as an <strong>adverse effect of levodopa.</strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 58333,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14500,
      "choices": [
        {
          "id": 57961,
          "text": "<p><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flumazenil</span></span></p>"
        },
        {
          "id": 57962,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Beta carboline</span></span></span></p>"
        },
        {
          "id": 57963,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Naltrexone</span></span></span></p>"
        },
        {
          "id": 57964,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Zopiclone</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which drug has inverse agonist activity at benzodiazepine receptors? </span></span></span></p>",
      "unique_key": "Q8955635",
      "question_audio": null,
      "question_video": null,
      "map_id": 36232,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Beta carboline</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Beta-carbolines</span></strong><span style=\"font-size:12.0pt\"> are compounds that have been identified to possess <strong>inverse agonist activity </strong>at the<strong> benzodiazepine site of the GABA-A receptor.</strong> Unlike <strong>benzodiazepines,</strong> which are<strong> agonists</strong> at this site and <strong>increase the inhibitory effect of GABA</strong> leading to <strong>sedation and anxiolysis, inverse agonists</strong> like<strong> beta-carbolines decrease the action of GABA</strong>. This can <strong>lead to effects opposite</strong> those of <strong>benzodiazepines</strong>, such as<strong> increased anxiety </strong>and <strong>seizures in susceptible individuals.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanatio:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Flumazenil</span></strong><span style=\"font-size:12.0pt\">: Flumazenil is a<strong> benzodiazepine receptor antagonist,</strong> <strong>not an inverse agonist</strong>. It is<strong> used to reverse</strong> the effects of <strong>benzodiazepines</strong> in cases of <strong>overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Naltrexone</span></strong><span style=\"font-size:12.0pt\">: Naltrexone is an <strong>opioid receptor antagonist</strong> used primarily in the management of<strong> alcohol and opioid</strong> <strong>dependence</strong>, <strong>not</strong> related to<strong> benzodiazepine receptor</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Zopiclone</span></strong><span style=\"font-size:12.0pt\">: Zopiclone is a <strong>non-benzodiazepine hypnotic agent </strong>used for the treatment of <strong>insomnia.</strong> It <strong>acts </strong>as an <strong>agonist</strong> at the<strong> benzodiazepine site of the GABA-A receptor</strong>, similar to <strong>benzodiazepines,</strong> but it is <strong>not an inverse agonist.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to understand the concept of<strong> inverse agonism at the benzodiazepine receptors</strong>, <strong>exemplified by compounds</strong> such as <strong>beta-carbolines</strong>. This understanding <strong>highlights</strong> the <strong>diversity of drug actions at the GABA-A receptor complex</strong>, ranging from <strong>agonists (e.g., benzodiazepines)</strong> that enhance <strong>GABAergic activity to inverse agonists</strong> that <strong>reduce this activity,</strong> with significant <strong>implications</strong> for<strong> their effects</strong> on the<strong> central nervous system.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS ACTING AT GABA-BZD-CHLORIDE CHANNEL COMPLEX</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-151400.jpg\" style=\"height:549px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 57962,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14623,
      "choices": [
        {
          "id": 58453,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sibutramine</span></span></span></p>"
        },
        {
          "id": 58454,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fenfluramine</span></span></span></p>"
        },
        {
          "id": 58455,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Metformin</span></span></span></p>"
        },
        {
          "id": 58456,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liraglutide </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following drugs is used in the treatment of obesity? </span></span></span></p>",
      "unique_key": "Q2748236",
      "question_audio": null,
      "question_video": null,
      "map_id": 36242,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Liraglutide </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Liraglutide</strong> is a<strong> GLP-1 receptor agonist </strong>that is approved for the <strong>treatment of obesity.</strong> It works by<strong> mimicking the action of the GLP-1 hormone</strong>, which is involved in <strong>appetite regulation </strong>and <strong>calorie intake</strong>. Liraglutide <strong>promotes weight loss </strong>by <strong>increasing feelings of fullness</strong>, <strong>reducing</strong> <strong>hunger,</strong> and thereby<strong> lowering calorie intake. </strong>It is<strong> administered via injection</strong> and is used as <strong>part of a comprehensive weight management </strong>program that includes <strong>diet, exercise</strong>, and <strong>behavior modification.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri, sans-serif\"><span style=\"font-size:16px\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sibutramine:</span></strong><span style=\"font-size:12.0pt\"> Sibutramine was<strong> previously used </strong>for the treatment of <strong>obesity.</strong> However, it was <strong>withdrawn from the market </strong>in many countries due to <strong>concerns</strong> over <strong>cardiovascular side effects,</strong> including<strong> increased risk of heart attack and stroke</strong>. Therefore, it is<strong> no</strong> longer<strong> recommended or available </strong>as a <strong>treatment option</strong> for <strong>obesity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fenfluramine:</span></strong><span style=\"font-size:12.0pt\"> Fenfluramine, <strong>part of the fen-phen combination,</strong> was used in the <strong>past for weight loss</strong>. However, it was <strong>withdrawn from the market</strong> <strong>due to</strong> its association with <strong>serious</strong> <strong>heart valve problems and pulmonary hypertension</strong>. It is <strong>no longer </strong>available or recommended for the <strong>treatment of obesity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. &nbsp;Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin is primarily <strong>used for</strong> the treatment of <strong>type 2 diabetes</strong>. While it is<strong> not</strong> approved specifically for the <strong>treatment of obesity, </strong>it may<strong> lead to modest</strong> <strong>weight loss </strong>in some<strong> individuals,</strong> especially those with<strong> insulin resistance</strong>. However,<strong> its primary</strong> indication is <strong>not obesity treatment</strong>, and it is used <strong>off-label for weight management</strong> in certain cases.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective of this question is to know different drugs like <strong>liraglutide </strong>which are <strong>used in treatment of obesity. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">US-FDA APPROVED ANTI-OBESITY DRUGS:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/1030.jpg\" style=\"height:824px; width:1000px\" /></p>",
      "correct_choice_id": 58456,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14458,
      "choices": [
        {
          "id": 57793,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GABA A-BZD - CI- channel stimulator </span></span></span></p>"
        },
        {
          "id": 57794,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GABA B-BZD - CI- channel stimulator </span></span></span></p>"
        },
        {
          "id": 57795,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BZD receptor stimulator </span></span></span></p>"
        },
        {
          "id": 57796,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NMDA receptor stimulator</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male patient with a history of anxiety and insomnia has been prescribed a benzodiazepine medication by his psychiatrist. Which of the following is the mechanism of action of benzodiazepine?</span></span></span></p>",
      "unique_key": "Q3635312",
      "question_audio": null,
      "question_video": null,
      "map_id": 36240,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) GABA A-BZD - CI- channel stimulator</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Benzodiazepines </strong>enhance the <strong>inhibitory neurotransmission mediated by GABA (gamma-aminobutyric acid) </strong>in the central nervous system. They<strong> bind</strong> to a <strong>specific site on the GABA A receptor complex</strong>, <strong>distinct from the GABA binding site</strong> but closely associated with it. This <strong>binding increases the frequency of chloride ion channel openings </strong>in response to <strong>GABA binding</strong>, leading to<strong> increased</strong> <strong>chloride ion influx. </strong>The <strong>influx of chloride</strong> ions results in<strong> hyperpolarization of neurons,</strong> making them<strong> less excitable </strong>and thereby producing a <strong>calming effect</strong>. This mechanism is critical in treating conditions like<strong> anxiety and insomnia</strong> by effectively <strong>reducing</strong> <strong>neuronal excitability and activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. GABA B-BZD - CI- channel stimulator:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>because<strong> benzodiazepines</strong> <strong>do not act </strong>on <strong>GABA B receptors</strong>, which primarily involve <strong>different signaling mechanisms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BZD receptor stimulator:</span></strong><span style=\"font-size:12.0pt\"><strong> Misleading</strong> as <strong>benzodiazepines enhance GABA&#39;s effect</strong> rather than<strong> directly stimulating</strong> the <strong>receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. NMDA receptor stimulator:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> because <strong>benzodiazepines do not </strong>interact with <strong>NMDA receptors,</strong> which are involved in<strong> excitatory neurotransmission.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Benzodiazepines </strong>function by<strong> stimulating chloride ion channels</strong> associated with the<strong> GABA A receptor complex,</strong> enhancing the <strong>natural inhibitory effects of GABA</strong>, which is <strong>crucial for</strong> their efficacy in <strong>treating anxiety and insomnia.</strong></span></span></p>",
      "correct_choice_id": 57793,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14621,
      "choices": [
        {
          "id": 58445,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tourette syndrome</span></span></span></p>"
        },
        {
          "id": 58446,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Post-traumatic stress disorder</span></span></span></p>"
        },
        {
          "id": 58447,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Bipolar disorder</span></span></span></p>"
        },
        {
          "id": 58448,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Dementia </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following is not an off-label use of risperidone?&nbsp; </span></span></span></p>",
      "unique_key": "Q6727836",
      "question_audio": null,
      "question_video": null,
      "map_id": 36241,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Ans. C) &nbsp;Bipolar disorder</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Off-label </strong>use of a drug refers to the <strong>use of a medication for a purpose </strong>that <strong>has not</strong> been approved by <strong>regulatory agencies,</strong> such as the <strong>US Food and Drug Administration (FDA).</strong> <strong>Risperidone </strong>is approved for the <strong>treatment of Psychosis and Bipolar disorder</strong>. So, <strong>bipolar</strong> <strong>disorder</strong> is <strong>not an off-label use of risperidone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Some Off-Label Uses of Risperidone are:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tourette&#39;s syndrome</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obsessive-compulsive disorder (OCD)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post-traumatic stress disorder (PTSD)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Management of behavioural and psychological symptoms in dementia</span><strong> </strong></span></span></li>\r\n</ul>",
      "correct_choice_id": 58447,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14481,
      "choices": [
        {
          "id": 57885,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dimethyl fumarate (DMF)</span></span></span></p>"
        },
        {
          "id": 57886,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Interferon-&beta;-1a</span></span></span></p>"
        },
        {
          "id": 57887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fingolimod</span></span></span></p>"
        },
        {
          "id": 57888,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Natalizumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 38-year-old woman has relapsing/remitting multiple sclerosis. She has experienced two attacks of disease previously that have left her with residual lower extremity weakness. She was initially treated with glucocorticoids with some improvement in her symptoms. However, she is currently only able to walk with a rolling walker for about 100 m. A prior antibody test shows positive reactivity to the JC virus. You are planning to start disease-modifying therapy. Which of the following is LEAST appropriate for this individual?</span></span></span></p>",
      "unique_key": "Q5647149",
      "question_audio": null,
      "question_video": null,
      "map_id": 36238,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Natalizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Natalizumab</strong> is an <strong>effective disease-modifying therapy </strong>for <strong>relapsing forms of multiple sclerosis</strong> but carries a <strong>significant risk </strong>for <strong>progressive multifocal leukoencephalopathy (PML)</strong>, especially in patients who are<strong> JC virus antibody positive</strong>. Given this patient&#39;s <strong>positive JC virus antibody status</strong>, the<strong> risk of developing PML</strong> with <strong>natalizumab treatment</strong> is considerably<strong> higher,</strong> making it the<strong> least</strong> appropriate <strong>option for her.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dimethyl fumarate (DMF):</span></strong><span style=\"font-size:12.0pt\"> Suitable for <strong>relapsing-remitting MS</strong> with a different <strong>safety profile</strong> and <strong>lower risk of PML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Interferon-&beta;-1a:</span></strong><span style=\"font-size:12.0pt\"> <strong>Commonly</strong> used in<strong> MS</strong>, works by <strong>modulating the immune system</strong> and also has a <strong>lower risk of PML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fingolimod:</span></strong><span style=\"font-size:12.0pt\"> Although it requires <strong>monitoring for other side effects</strong>, it has a <strong>lesser association with PML</strong> compared to natalizumab in <strong>JC virus positive patients.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In<strong> multiple sclerosis patients</strong> who are <strong>JC virus antibody positive</strong>, <strong>natalizumab</strong> presents an<strong> increased risk of PML</strong> and <strong>should be used</strong> with <strong>caution or avoided </strong>in favor of<strong> therapies with a safer profile </strong>under <strong>such conditions.</strong></span></span></p>",
      "correct_choice_id": 57888,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14509,
      "choices": [
        {
          "id": 57997,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old male with a history of stable angina who presents with chest pain.</span></span></span></p>"
        },
        {
          "id": 57998,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old female with metastatic breast cancer and severe pain.</span></span></span></p>"
        },
        {
          "id": 57999,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old male with a history of biliary colic who presents with abdominal pain.</span></span></span></p>"
        },
        {
          "id": 58000,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old female who underwent a minor surgical procedure and is experiencing postoperative pain.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following patients should not receive morphine?</span></span></span></p>",
      "unique_key": "Q8256132",
      "question_audio": null,
      "question_video": null,
      "map_id": 36237,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) A 30-year-old male with a history of biliary colic who presents with abdominal pain.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Morphine</strong> can <strong>exacerbate biliary colic</strong> by causing <strong>spasm of the sphincter of Oddi,</strong> which controls the <strong>flow of bile into the intestine</strong>. This spasm can <strong>lead to an increase in biliary tract pressure </strong>and<strong> worsen pain</strong> in patients with <strong>biliary colic</strong>. Alternatives such as <strong>non</strong>-<strong>opioid analgesics</strong> or <strong>other opioids less</strong> likely to<strong> induce biliary spasm</strong>, like <strong>pethidine (meperidine),</strong> may be considered in such cases.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\"><strong>&nbsp;Morphine</strong> is generally <strong>safe for patients</strong> with<strong> stable angina,</strong> provided it is used<strong> cautiously</strong> under<strong> medical supervision.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">&nbsp;Suitable for managing<strong> severe cancer pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">&nbsp;Appropriate for <strong>controlling moderate to severe postoperative pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Precautions and contraindications while using morphine.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Morphine</strong> releases <strong>histamine</strong> which can cause <strong>bronchoconstriction. </strong>Therefore, <strong>avoided in patients</strong> of <strong>respiratory</strong> <strong>insufficiency.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Morphine</strong> causes <strong>spasm of sphincter of Oddi </strong>due to which <strong>intrabiliary pressure is increased</strong>, hence causing <strong>worsening of pain due to biliary colic.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Morphine</strong> causes <strong>spasm of both detrusor muscle and urinary sphincter,</strong> hence <strong>urinary urgency</strong> and<strong> difficulty in</strong> <strong>micturition </strong>can occur.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In<strong> case of head injury,</strong> morphine is<strong> contraindicated</strong> due to following reasons:</span></span></span>\r\n\t<ol style=\"list-style-type:lower-roman\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Increases intracranial tension </strong>by <strong>retaining CO<sub>2.</sub></strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Marked<strong> respiratory depression</strong> even <strong>at therapeutic doses</strong> in patients of<strong> head injury.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Morphine produces <strong>miosis, vomiting, and altered mental status</strong> which can interfere with assessment of patients.</span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ol>",
      "correct_choice_id": 57999,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14611,
      "choices": [
        {
          "id": 58405,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pimavanserin </span></span></span></p>"
        },
        {
          "id": 58406,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Riluzole </span></span></span></p>"
        },
        {
          "id": 58407,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fingolimod </span></span></span></p>"
        },
        {
          "id": 58408,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tetrabenazine</span><strong> </strong></span></span><strong> </strong></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 72-year-old woman with a history of Parkinson&#39;s disease presents with new-onset hallucinations and delusions. Her neurologist is considering adding a medication to address these symptoms without worsening her motor symptoms. Which of the following medications would be most appropriate for this patient?</span></span></span></p>",
      "unique_key": "Q9950832",
      "question_audio": null,
      "question_video": null,
      "map_id": 36239,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Pimavanserin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pimavanserin </strong>is a <strong>selective serotonin inverse agonist</strong> that specifically<strong> targets</strong> the <strong>5-HT2A receptor.</strong> It is approved for the <strong>treatment of Parkinson&#39;s disease</strong> <strong>psychosis, </strong>which can manifest as<strong> hallucinations and delusions</strong>. <strong>Pimavanserin</strong> <strong>does not</strong> affect <strong>dopamine levels</strong>, which makes it a<strong> suitable choice</strong> for patients with<strong> Parkinson&#39;s disease,</strong> as it is <strong>less likely</strong> to <strong>worsen motor </strong>symptoms compared to <strong>traditional antipsychotics.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Riluzole is</span></strong><span style=\"font-size:12.0pt\"> primarily used to treat <strong>amyotrophic lateral sclerosis (ALS).</strong> It is thought to work by <strong>reducing the release of the neurotransmitter glutamate,</strong> which may <strong>slow down</strong> the<strong> progression of ALS. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fingolimod&nbsp;</span></strong><span style=\"font-size:12.0pt\">is used to treat<strong> multiple sclerosis (MS). </strong>It is a<strong> sphingosine-1-phosphate</strong> <strong>receptor modulator,</strong> which works by<strong> sequestering lymphocytes in the lymph nodes</strong>, <strong>reducing</strong> their ability to contribute to the <strong>autoimmune response in MS. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tetrabenazine</span></strong><span style=\"font-size:12.0pt\"> is used to <strong>treat chorea</strong> associated with<strong> Huntington&#39;s disease</strong>. It works by<strong> inhibiting the vesicular monoamine transporter 2 (VMAT2),</strong> leading to a <strong>decrease</strong> in the <strong>release of dopamine in the brain.</strong> Although it may have some <strong>antipsychotic properties</strong>, <strong>tetrabenazine</strong> is <strong>not</strong> the most appropriate <strong>choice</strong> for treating<strong> hallucinations</strong> and <strong>delusions in Parkinson&#39;s disease</strong> patients, as it can exacerbate <strong>motor symptoms </strong>due to its <strong>dopamine-depleting effects.</strong></span></span></span></p>",
      "correct_choice_id": 58405,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14618,
      "choices": [
        {
          "id": 58433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Serum electrolytes </span></span></span></p>"
        },
        {
          "id": 58434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Serum lithium levels</span></span></span></p>"
        },
        {
          "id": 58435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ECG </span></span></span></p>"
        },
        {
          "id": 58436,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MRI</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female patient who has been on lithium therapy for bipolar disorder for 6 months presents with seizures, coarse tremors, confusion, and weakness of limbs after fasting for a few days due to religious reasons. To diagnose her condition, the following test should be performed:</span></span></p>",
      "unique_key": "Q3294249",
      "question_audio": null,
      "question_video": null,
      "map_id": 36236,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Serum lithium levels</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>patient&#39;s symptoms</strong> are suggestive of<strong> lithium toxicity,</strong> which can be <strong>confirmed by measuring serum lithium levels. Fasting and dehydration</strong> may have contributed to the <strong>development of lithium toxicity,</strong> as they can cause <strong>reduced renal clearance and increased reabsorption of lithium</strong>, leading to <strong>higher serum concentrations.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Other Options:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option A. Serum electrolytes:&nbsp;</strong> It would also be important to evaluate the <strong>patient&#39;s serum electrolytes </strong>&nbsp;to assess for any<strong> imbalances</strong> that may have <strong>resulted from fasting or lithium toxicity.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Option C. ECG:</strong>&nbsp; An <strong>ECG&nbsp;&nbsp;</strong>may be necessary to<strong> check</strong> for any <strong>cardiac abnormalities, </strong>as <strong>lithium </strong>can<strong> sometimes affect the heart.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D. MRI:</strong>&nbsp;An<strong> MRI (D)</strong> may be considered if there is concern for other <strong>underlying neurological issues</strong>, but it is <strong>not</strong> the<strong> first step</strong> in <strong>diagnosing lithium toxicity.</strong></span></span></p>",
      "correct_choice_id": 58434,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14502,
      "choices": [
        {
          "id": 57969,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MAO B inhibitor </span></span></span></p>"
        },
        {
          "id": 57970,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibitor of vesicular monoamine transporter </span></span></span></p>"
        },
        {
          "id": 57971,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibitor of dopamine receptors </span></span></span></p>"
        },
        {
          "id": 57972,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibitor of COMT</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 45-year-old male with a history of Huntington&#39;s disease presents to the clinic with significant chorea. He is taking tetrabenazine to help control his symptoms. What is the mechanism of action of tetrabenazine? </span></span></span></p>",
      "unique_key": "Q9110465",
      "question_audio": null,
      "question_video": null,
      "map_id": 36234,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Inhibitor of vesicular monoamine transporter</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Tetrabenazine</strong> acts as an<strong> inhibitor of the vesicular monoamine transporter 2 (VMAT2),</strong> which is involved in the <strong>uptake of</strong> <strong>monoamines, including dopamine, into synaptic vesicles</strong>. By <strong>inhibiting this transporter</strong>,<strong> tetrabenazine reduces </strong>the amount of <strong>dopamine</strong> available for <strong>release into the synapse.</strong> This<strong> reduction in dopamine release</strong> is <strong>beneficial</strong> in managing symptoms like <strong>chorea</strong> <strong>in Huntington&#39;s disease,</strong> which are partly caused by<strong> excessive dopaminergic activity</strong> in certain<strong> brain regions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MAO B inhibitor:</span></strong><span style=\"font-size:12.0pt\"> These are typically<strong> used in Parkinson&#39;s disease</strong> to<strong> increase dopamine availability</strong> and <strong>are not </strong>relevant to the<strong> mechanism of tetrabenazine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibitor of dopamine receptors:</span></strong><span style=\"font-size:12.0pt\"> While<strong> blocking dopamine receptors</strong> can <strong>reduce chorea</strong>, <strong>tetrabenazine</strong> <strong>does not</strong> directly <strong>block these receptors but</strong> rather <strong>decreases dopamine availability.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibitor of COMT:</span></strong><span style=\"font-size:12.0pt\"> This class of drugs is also <strong>used in Parkinson&rsquo;s disease </strong>and is <strong>not </strong>involved in the <strong>mechanism of action </strong>of <strong>tetrabenazine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tetrabenazine&rsquo;s</strong> ability to<strong> inhibit VMAT2 </strong>and<strong> reduce dopamine release </strong>makes it <strong>effective for treating chorea</strong> associated with <strong>Huntington&#39;s disease, highlighting</strong> its role in <strong>managing hyperkinetic movement disorders.</strong></span></span></p>",
      "correct_choice_id": 57970,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}